Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20334
Title: The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.
Austin Authors: Lee, Carl;Greene, Shaun L ;Wong, Anselm Y 
Affiliation: Department of Medicine, School of Clinical Sciences , Monash University , Melbourne , Australia
Austin Health Clinical School, The University of Melbourne, Heidelberg, Victoria, Australia
Austin Toxicology Service, Austin Health, Heidelberg, Victoria, Australia
Victorian Poisons Information Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Sep-2019
metadata.dc.date: 2019-02-07
Publication information: Clinical toxicology (Philadelphia, Pa.) 2019; 57(9): 773-777
Abstract: Cannabinoid hyperemesis syndrome (CHS) can be characterized by recurrent paroxysmal episodes of intractable nausea and vomiting, abdominal pain, and compulsive hot showers/baths with symptom relief, on the background of chronic cannabis use. We reported the use of droperidol in the management of CHS. We performed a retrospective review of electronic medical records of Emergency Department presentations to a single tertiary level metropolitan hospital between January 2006 and December 2016 using search keywords: "cannabis", "cannabinoid", "cannabis", "hyperemesis", and "droperidol". A secondary search of pharmacy droperidol dispensing records was cross matched with electronic medical record data. We reviewed each record to determine if the presentation met previously published diagnostic criteria for CHS. Data were dichotomised into presentations with droperidol administered or not administered. The primary outcome was defined as the total length of hospital stay. Secondary outcomes measures included time until discharge following last drug administration, and the total number of antiemetic dosages administered. Six-hundred and eighty-nine records were identified and 76 met CHS diagnostic criteria. Thirty-seven presentations were treated with droperidol and 39 were not. Droperidol treatment group median length of stay was significantly lower compared to the no droperidol treatment group (6.7 vs. 13.9 hours, p = .014). Median time to discharge after final drug administration in the droperidol treatment group was 137 minutes (IQR 65, 203) vs. the no droperidol treatment group of 185 minutes (IQR 149, 403). The most frequent dosage of droperidol used was 0.625mg intravenously. The frequency of ondansetron (n = 100) and metoclopramide (n = 27) in the no droperidol treatment group was double that of the droperidol group. Use of droperidol to treat CHS associated nausea and vomiting resulted in less overall use of antiemetics and reduced length of stay.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20334
DOI: 10.1080/15563650.2018.1564324
ORCID: 0000-0002-7423-2467
0000-0002-6817-7289
PubMed URL: 30729854
Type: Journal Article
Subjects: Marijuana
cannabis
cyclical
nausea
vomiting
Appears in Collections:Journal articles

Show full item record

Page view(s)

18
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.